P =0.025 one-sided test) to a primary endpoint that would achieve an increase in IGF-I level at 1 month of at least 15%
In a Phase I study with recombinant human thymosin beta-4, the terminal half-life was about 0.5 to 2.08 hours, for example 1.02 hours at 0.5 microg/kg and up to 2.08 hours at 25 microg/kg, with linear, non-accumulating kinetics and dose-proportional Cmax Wang et al., 2021
Neither is universally superior
However, it is important to understand that animal research does not automatically translate to long-term safety in humans
This approach maximizes BPC-157's local effects while ensuring TB-500's systemic benefits reach all tissues
For anyone considering GHK-Cu, my advice is simple: give it time, stay consistent, and keep your expectations realistic